Program
HS-20152
A development code.
In Hansoh Pharmaceutical Group's pipeline, PNH
. Its studies are led by Hansoh Pharmaceutical Group.
Furthest: phase 1, since Mar 25, 20261 company-led study, 1 open or runningNext primary completion: Jan 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since Mar 25, 2026 | Mar 25, 2026 | Jan 1, 2027phase 1 · NCT07503015 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20152 (PNH)
, phase 1, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07503015 · 32 planned · China
Ahead
- Jan 1, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07503015
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“PNH”the company's pipeline, read by Claude · source
“This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study will evaluate the safety and tolerability of HS-20152, an investigational therapy targeting the complement pathway, in healthy adults.”study summary, read by Claude · the study
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07503015Healthy Volunteers · China | 1 | Not yet recruiting | Jan 1, 2027 | 32 |
How it is read
Names in the registry
- “HS-20152”, 1 entry
Codes read as this program: HS20152.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.